A new multidistrict litigation over the anti-nausea drug Zofran could be coming to Pennsylvania pending the outcome of a hearing before a federal judicial panel in roughly two weeks.

On Oct. 1, the U.S. Judicial Panel on Multidistrict Litigation is set to consider whether the 12 Zofran cases filed this year from across the country should be consolidated in the U.S. District Court for the Eastern District of Pennsylvania.

The motion to consolidate the cases was filed by defendant GlaxoSmithKline, the maker of Zofran. The plaintiffs in the cases allege taking Zofran during pregnancy caused their children to be born with birth defects.